Equities research analysts forecast that Simulations Plus, Inc. (NASDAQ:SLP) will announce $11.17 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Simulations Plus’ earnings, with the highest sales estimate coming in at $11.24 million and the lowest estimate coming in at $11.10 million. Simulations Plus posted sales of $10.70 million in the same quarter last year, which suggests a positive year-over-year growth rate of 4.4%. The business is expected to announce its next quarterly earnings results on Monday, January 10th.
According to Zacks, analysts expect that Simulations Plus will report full year sales of $51.47 million for the current financial year, with estimates ranging from $51.03 million to $51.92 million. For the next financial year, analysts expect that the firm will report sales of $62.36 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Simulations Plus.
Simulations Plus (NASDAQ:SLP) last posted its earnings results on Sunday, October 24th. The technology company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.04). The firm had revenue of $9.84 million during the quarter, compared to analyst estimates of $8.14 million. Simulations Plus had a net margin of 21.05% and a return on equity of 6.01%. During the same quarter in the previous year, the business posted $0.12 earnings per share.
SLP traded down $1.03 during mid-day trading on Thursday, reaching $51.04. The stock had a trading volume of 121,161 shares, compared to its average volume of 172,017. Simulations Plus has a 52 week low of $36.90 and a 52 week high of $90.92. The company has a market cap of $1.03 billion, a PE ratio of 110.96, a P/E/G ratio of 7.51 and a beta of 0.07. The stock has a fifty day moving average price of $46.00.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 1st. Stockholders of record on Monday, October 25th were issued a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 0.47%. The ex-dividend date of this dividend was Friday, October 22nd. Simulations Plus’s dividend payout ratio (DPR) is 52.17%.
In related news, Director Walter S. Woltosz sold 8,803 shares of the firm’s stock in a transaction on Monday, August 30th. The stock was sold at an average price of $44.90, for a total transaction of $395,254.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 28th. The stock was sold at an average price of $38.54, for a total value of $770,800.00. The disclosure for this sale can be found here. Insiders sold 58,503 shares of company stock worth $2,505,754 over the last three months. 23.24% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC increased its position in Simulations Plus by 57.2% in the second quarter. Steward Partners Investment Advisory LLC now owns 929 shares of the technology company’s stock worth $51,000 after buying an additional 338 shares during the period. Advisors Asset Management Inc. increased its position in Simulations Plus by 67.5% in the second quarter. Advisors Asset Management Inc. now owns 1,191 shares of the technology company’s stock worth $65,000 after buying an additional 480 shares during the period. FORA Capital LLC acquired a new stake in Simulations Plus in the first quarter worth $120,000. FinTrust Capital Advisors LLC increased its position in Simulations Plus by 84.3% in the third quarter. FinTrust Capital Advisors LLC now owns 2,470 shares of the technology company’s stock worth $98,000 after buying an additional 1,130 shares during the period. Finally, Amundi acquired a new position in shares of Simulations Plus during the second quarter valued at $155,000. 70.85% of the stock is currently owned by hedge funds and other institutional investors.
About Simulations Plus
Simulations Plus, Inc provides modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. It operates through the following segments: Simulations Plus, Inc, Cognigen Corporation, DILIsym, and Lixoft. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students.
Featured Article: How does the Beige Book influence monetary policy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.